Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Lymphoma, Myeloma & Leukemia

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clml.2013.03.018PMID 23890944PMCID PMC4160831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

  2016cited by this paper
• Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

  2012cited by this paper
• Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).

  2012cited by this paper
• Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

  2012cited by this paper
• BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

  2012cited by this paper
• Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

  2012cited by this paper
• Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper mutation

  2012cited by this paper
• Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

  2012cited by this paper
• BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

  2012cited by this paper
• Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2012cited by this paper
• Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

  2012cited by this paper
• Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

  2012cited by this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

  2012cited by this paper
• Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

  2012cited by this paper
• Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).

  2012cited by this paper
• Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

  2012cited by this paper
• Ponatinib in refractory Philadelphia chromosome-positive leukemias.

  2012cited by this paper
• Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

  2012cited by this paper
• Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

  2012cited by this paper
• Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

  2012cited by this paper
• A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

  2012cited by this paper
• Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

  2011cited by this paper
• The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

  2011cited by this paper
• Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

  2011cited by this paper
• The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

  2011cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011cited by this paper
• Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

  2011cited by this paper
• Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

  2011cited by this paper
• Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

  2011cited by this paper
• Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

  2011cited by this paper
• Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

  2011cited by this paper
• BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

  2011cited by this paper
• Mutational analysis in chronic myeloid leukemia: when and what to do?

  2011cited by this paper
• Omacetaxine as an anticancer therapeutic: what is old is new again.

  2011cited by this paper
• Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

  2011cited by this paper
• Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells

  2011cited by this paper
• Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.

  2011cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cited by this paper
• NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

  2011cited by this paper
• Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

  2011cited by this paper
• Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission.

  2011cited by this paper
• Monitoring response and resistance to treatment in chronic myeloid leukemia.

  2011cited by this paper
• Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review

  2011cited by this paper
• BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

  2010cited by this paper
• Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

  2010cited by this paper
• Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

  2010cited by this paper
• Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

  2010cited by this paper
• Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

  2010cited by this paper
• Resistance to imatinib: mutations and beyond.

  2010cited by this paper
• Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

  2010cited by this paper
• BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

  2010cited by this paper
• Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

  2010cited by this paper
• Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.

  2010cited by this paper
• Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

  2010cited by this paper
• Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

  2010cited by this paper
• Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

  2009cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

  2009cited by this paper
• Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

  2009cited by this paper
• Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.

  2009cited by this paper
• Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

  2009cited by this paper
• Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

  2009cited by this paper
• Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

  2009cited by this paper
• Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

  2009cited by this paper
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

  2009cited by this paper
• Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

  2009cited by this paper
• A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

  2009cited by this paper
• Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

  2009cited by this paper
• Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

  2009cited by this paper
• Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.

  2009cited by this paper
• Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

  2009cited by this paper
• Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

  2009cited by this paper
• Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

  2009cited by this paper
• Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

  2009cited by this paper
• Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

  2009cited by this paper
• Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

  2009cited by this paper
• Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

  2009cited by this paper
• Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

  2008cited by this paper
• Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

  2008cited by this paper
• Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

  2008cited by this paper
• Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

  2008cited by this paper
• Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

  2008cited by this paper
• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

  2008cited by this paper
• In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

  2008cited by this paper
• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

  2008cited by this paper
• A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

  2008cited by this paper
• Homoharringtonine for the treatment of chronic myelogenous leukemia

  2008cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

  2007cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

  2007cited by this paper
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

  2007cited by this paper
• Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors

  2007cited by this paper
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

  2007cited by this paper
• Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

  2007cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007cited by this paper
• Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors

  2007cited by this paper
• Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

  2007cited by this paper

• Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase.

  2026cites this paper
• p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia.

  2025cites this paper
• Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy

  2025cites this paper
• Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias

  2025cites this paper
• Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population

  2025cites this paper
• Systematic optimization of reverse phase ultra‐high‐performance liquid chromatography method for quantification of nilotinib and its related substances in bulk drug and pharmaceutical formulation using quality by design approach

  2024cites this paper
• The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.

  2024cites this paper
• High-throughput formulation of reproducible 3D cancer microenvironments for drug testing in myelogenous leukemia

  2024cites this paper
• The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.

  2024cites this paper
• Targeting the insulin-like growth factor-1 receptor to overcome imatinib resistance in chronic myeloid leukemia

  2024cites this paper
• Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis

  2024cites this paper
• Phenotypically plastic drug‐resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model

  2024cites this paper
• Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation

  2024cites this paper
• Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery

  2023cites this paper
• Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

  2023cites this paper
• The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

  2023cites this paper
• Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.

  2022cites this paper
• Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

  2022cites this paper
• Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

  2022cites this paper
• 1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line

  2022cites this paper
• Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia

  2022cites this paper
• Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review.

  2022cites this paper
• Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.

  2022cites this paper
• Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes

  2022cites this paper
• Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells

  2022cites this paper
• The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

  2021cites this paper
• Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells

  2021cites this paper
• The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.

  2021cites this paper
• Self-enhanced luminol-based electrochemiluminescent hydrogels: An ultrasensitive biosensing platform for fusion gene analysis coupled with target-initiated DNAzyme motor.

  2021cites this paper
• Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

  2021cites this paper
• Protein flexibility and dissociation pathway differentiation can explain onset of resistance mutations in kinases

  2021cites this paper
• Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

  2021cites this paper
• The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia

  2021cites this paper
• Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors

  2021cites this paper
• Study on Mutation Resistance to Imatinib in Chronic Myeloid Leukemia Patients from West India

  2021cites this paper
• Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.

  2021cites this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cites this paper
• MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

  2020cites this paper
• Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

  2020cites this paper
• HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

  2020influential citation
• The regulation of bcr-abl in hypoxia is through the mTOR pathway

  2020cites this paper
• Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase

  2020cites this paper
• Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

  2020cites this paper
• A Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia

  2020cites this paper
• Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia.

  2019cites this paper
• Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

  2019cites this paper
• Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

  2019cites this paper
• Drug resistance and combating drug resistance in cancer

  2019cites this paper
• Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.

  2019cites this paper
• Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

  2019cites this paper
• Evaluation of 389nm UV-LED to Induce Apoptosis in Leukemia Cells for Develop Implant Photonics-Device

  2019cites this paper
• CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

  2019cites this paper
• ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ПОЛИМОРФНЫХ ВАРИАНТОВ ГЕНОВ CYP3A5 И hOCT1 У БОЛЬНЫХ ХРОНИЧЕСКИМ МИЕЛОЛЕЙКОЗОМ В РЕСПУБЛИКЕ БАШКОРТОСТАН

  2019cites this paper
• PROGNOSTIC VALUE OF CYP3A5 AND hOCT1 POLYMORPHIC GENE VARIANTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF BASHKORTOSTAN

  2019cites this paper
• Colorimetric determination of BCR/ABL fusion genes using a nanocomposite consisting of Au@Pt nanoparticles covered with a PAMAM dendrimer and acting as a peroxidase mimic

  2018cites this paper
• Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung

  2018cites this paper
• Multi-omic profiling of TKI resistant K562 cells suggests metabolic reprogramming to promote cell survival

  2018cites this paper
• Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report

  2018cites this paper
• Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

  2018cites this paper
• Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia

  2017cites this paper
• Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

  2017cites this paper
• Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

  2017cites this paper
• BIRC6 mediates imatinib resistance independently of Mcl-1

  2017cites this paper
• Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

  2017cites this paper
• CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

  2017cites this paper
• PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

  2017cites this paper
• Kinase Inhibitors in Multitargeted Cancer Therapy.

  2017cites this paper
• ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells

  2016cites this paper
• EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins

  2016cites this paper
• Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

  2016cites this paper
• Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

  2016cites this paper
• Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance

  2016cites this paper
• Resisting Resistance: Targeted Therapies in Lung Cancer.

  2016cites this paper
• Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.

  2015cites this paper
• Differential expression of SHP-1 in chronic myeloid leukemia

  2015cites this paper
• Update on emerging treatments for chronic myeloid leukemia

  2015cites this paper
• Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.

  2015cites this paper
• Should vascular effects of newer treatments be addressed more completely?

  2015cites this paper
• Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield.

  2015cites this paper
• [Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].

  2015cites this paper
• Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia

  2015cites this paper
• Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

  2015cites this paper
• Sensitization of Chemo-Resistant Human Chronic Myeloid Leukemia Stem-Like Cells to Hsp90 Inhibitor by SIRT1 Inhibition

  2015cites this paper
• Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.

  2015cites this paper
• Analogs, formulations and derivatives of imatinib: a patent review

  2015cites this paper
• Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia

  2015cites this paper
• Resveratrol induces apoptosis in K562 cells via the regulation of mitochondrial signaling pathways.

  2015cites this paper
• Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

  2015cites this paper
• Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

  2015cites this paper
• The Role of Pharmacogenomics in Individualized Medicine

  2015cites this paper
• Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib

  2015influential citation
• Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

  2015cites this paper
• CBP/Catenin Antagonist Safely Eliminates Drug Resistant Leukemia Initiating Cells

  2015cites this paper
• Induction of Heme Oxygenase-1 by Na+-H+ Exchanger 1 Protein Plays a Crucial Role in Imatinib-resistant Chronic Myeloid Leukemia Cells*

  2015cites this paper
• Just caring: assessing the ethical and economic costs of personalized medicine.

  2014cites this paper
• A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields.

  2014cites this paper
• Multidrug resistance in chronic myeloid leukemia

  2014cites this paper
• Understanding life and death decisions in human leukaemias.

  2014cites this paper